RDY
Dr. Reddy's Laboratories Limited
Price Chart
Latest Quote
$13.29
+0.14 (+1.06%)
Current Price
| Previous Close | $13.15 |
| Open | $13.30 |
| Day High | $13.36 |
| Day Low | $13.21 |
| Volume | 1,332,021 |
Stock Information
Note: Financial values converted from INR to USD
| Quarterly Dividend / Yield | $0.08 / 0.63% |
| Shares Outstanding | 832.71M |
| Quarterly Dividend Yield | 0.63% |
| Quarterly Dividend | $0.08 |
| Total Debt | $820.07M |
| Cash Equivalents | $931.12M |
| Revenue | $3.56B |
| Net Income | $454.35M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $11.07B |
| P/E Ratio | 24.61 |
| EPS (TTM) | $0.54 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $59.19B |
| Sales | $3.56B |
| Income | $454.35M |
| Book/sh | $0.80 |
| Cash/sh | $105.46 |
| Employees | 28K |
Financial Ratios
| Quick Ratio | 1.13 |
| Current Ratio | 1.80 |
| Debt/Eq | 20.33 |
| EPS Growth TTM | -86.20% |
Returns & Margins
| ROA | 5.74% |
| ROE | 11.83% |
| Gross Margin | 52.77% |
| Operating Margin | 1.54% |
| Profit Margin | 12.76% |
Ownership
| Institutional Ownership | 15.29% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 19.80 |
| PEG | 1.59 |
| P/S | 0.03 |
| P/B | 16.72 |
Analyst Data
| Recommendation | hold |
| Target Price | $14.31 |
Technical Indicators
| SMA20 | $13.35 |
| SMA50 | $13.35 |
| SMA200 | $13.85 |
| RSI | 38.82 |
| ATR | 0.2100 |
| Shares Float | 3.59B |
| Short Float | 3.26% |
| Short Ratio | 8.29 |
| Volatility | 0.26 |
| Rel Volume | 1.31 |
Performance History
| Week | -0.52% |
| Month | -1.19% |
| Quarter | -6.01% |
| 6 Months | -4.46% |
| YTD | -4.11% |
| Year | -12.31% |
| 3 Years | +18.15% |
| 5 Years | -5.55% |
| 10 Years | +58.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $13.29 | 2,007,800 |
| 2026-06-17 | $13.15 | 2,891,600 |
| 2026-06-16 | $13.30 | 1,611,700 |
| 2026-06-15 | $13.33 | 1,018,200 |
| 2026-06-12 | $13.30 | 1,173,700 |
| 2026-06-11 | $13.36 | 1,172,000 |
| 2026-06-10 | $13.30 | 1,233,800 |
| 2026-06-09 | $13.37 | 1,676,000 |
| 2026-06-08 | $13.23 | 1,370,700 |
| 2026-06-05 | $13.24 | 1,092,600 |
| 2026-06-04 | $13.24 | 1,309,300 |
| 2026-06-03 | $13.02 | 1,340,000 |
| 2026-06-02 | $13.03 | 1,888,200 |
| 2026-06-01 | $13.26 | 1,744,100 |
| 2026-05-29 | $13.63 | 1,598,100 |
| 2026-05-28 | $13.52 | 1,481,100 |
| 2026-05-27 | $13.58 | 2,159,800 |
| 2026-05-26 | $13.75 | 1,297,500 |
| 2026-05-22 | $13.60 | 723,700 |
| 2026-05-21 | $13.55 | 1,836,500 |
| 2026-05-20 | $13.63 | 1,805,800 |
| 2026-05-19 | $13.45 | 2,177,200 |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
đ° Latest News
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
MT Newswires âĸ 2026-06-18T14:43:40ZAsian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT Newswires âĸ 2026-06-08T14:43:23ZAsian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
MT Newswires âĸ 2026-06-05T14:38:00ZAsian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading
MT Newswires âĸ 2026-06-01T14:40:39ZAsian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
MT Newswires âĸ 2026-05-29T14:40:32ZAsian Equities Traded in US as ADRs Fall in Wednesday Trading
MT Newswires âĸ 2026-05-27T14:37:46ZAsian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
MT Newswires âĸ 2026-05-26T14:41:33ZAsian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
MT Newswires âĸ 2026-05-15T14:38:39ZAsian Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
MT Newswires âĸ 2026-05-14T14:44:46ZDr. Reddy's Laboratories Q4 Earnings Call Highlights
MarketBeat âĸ 2026-05-14T12:09:30Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,667,742,330 | $1,420,086,236 | $1,214,599,578 | $1,119,781,412 |
| Cost Of Revenue | $1,667,742,330 | $1,420,086,236 | $1,214,599,578 | $1,119,781,412 |
| Total Revenue | $3,530,933,479 | $3,421,641,905 | $2,934,244,369 | $2,584,391,509 |
| Operating Revenue | $3,530,933,479 | $3,421,641,905 | $2,934,244,369 | $2,584,391,509 |
| Expenses | ||||
| Interest Expense | $39,289,469 | $29,735,128 | $17,984,024 | $15,009,460 |
| Total Expenses | $3,004,099,322 | $2,664,715,245 | $2,247,803,312 | $1,963,685,161 |
| Other Income Expense | $49,463,950 | $51,734,288 | $63,012,405 | $16,407,400 |
| Other Non Operating Income Expenses | $142,779,067 | $115,335,299 | - | - |
| Net Non Operating Interest Income Expense | $-126,130 | $-1,597,646 | $5,959,639 | $-2,606,685 |
| Interest Expense Non Operating | $39,289,469 | $29,735,128 | $17,984,024 | $15,009,460 |
| Operating Expense | $1,336,356,992 | $1,244,629,009 | $1,033,203,734 | $843,903,749 |
| Other Operating Expenses | $-38,679,842 | $-29,808,704 | $-18,656,717 | $-74,816,063 |
| General And Administrative Expense | $629,693,105 | $586,504,119 | - | - |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $450,388,916 | $594,324,174 | $585,284,863 | $473,691,418 |
| Net Interest Income | $-126,130 | $-1,597,646 | $5,959,639 | $-2,606,685 |
| Interest Income | $39,163,340 | $28,137,483 | $23,943,663 | $12,402,775 |
| Normalized Income | $413,386,181 | $557,234,095 | $537,955,032 | $464,302,622 |
| Net Income From Continuing And Discontinued Operation | $450,388,916 | $594,324,174 | $585,284,863 | $473,691,418 |
| Total Operating Income As Reported | $531,332,790 | $755,129,308 | $711,887,768 | $600,630,670 |
| Net Income Common Stockholders | $450,388,916 | $594,324,174 | $585,284,863 | $473,691,418 |
| Net Income | $450,388,916 | $594,324,174 | $585,284,863 | $473,691,418 |
| Net Income Including Noncontrolling Interests | $446,352,758 | $601,692,263 | $585,284,863 | $473,691,418 |
| Net Income Continuous Operations | $446,352,758 | $601,692,263 | $585,284,863 | $473,691,418 |
| Pretax Income | $576,171,976 | $807,063,302 | $755,413,101 | $634,507,063 |
| Special Income Charges | $4,498,634 | $-1,797,351 | $25,446,711 | $-20,075,679 |
| Earnings From Equity Interest | $1,408,451 | $2,280,849 | $1,545,091 | $3,889,006 |
| Interest Income Non Operating | $39,163,340 | $28,137,483 | $23,943,663 | $12,402,775 |
| Operating Income | $526,834,157 | $756,926,660 | $686,441,057 | $620,706,348 |
| Depreciation Amortization Depletion Income Statement | $216,396,896 | $179,072,951 | - | - |
| Depreciation And Amortization In Income Statement | $216,396,896 | $179,072,951 | - | - |
| Gross Profit | $1,863,191,149 | $2,001,555,669 | $1,719,644,791 | $1,464,610,097 |
| Per Share | ||||
| Diluted EPS | $0.54 | $0.71 | $0.70 | $0.57 |
| Basic EPS | $0.54 | $0.71 | $0.70 | $0.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $11,052,765 | $12,363,360 | $14,137,482 | $3,129,599 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $783,981,527 | $966,638,670 | $867,920,987 | $769,812,933 |
| Total Unusual Items | $48,055,499 | $49,453,439 | $61,467,313 | $12,518,394 |
| Total Unusual Items Excluding Goodwill | $48,055,499 | $49,453,439 | $61,467,313 | $12,518,394 |
| Reconciled Depreciation | $216,575,580 | $179,293,678 | $155,991,176 | $132,814,804 |
| EBITDA (Bullshit earnings) | $832,037,026 | $1,016,092,109 | $929,388,301 | $782,331,327 |
| EBIT | $615,461,446 | $836,798,430 | $773,397,125 | $649,516,524 |
| Diluted Average Shares | $8,759,005 | $8,767,912 | $8,761,221 | $8,744,084 |
| Basic Average Shares | $8,749,639 | $8,754,997 | $8,744,756 | $8,725,724 |
| Diluted NI Availto Com Stockholders | $450,388,916 | $594,324,174 | $585,284,863 | $473,691,418 |
| Minority Interests | $4,036,157 | $-7,368,089 | $0 | $0 |
| Tax Provision | $129,819,218 | $205,371,039 | $170,128,238 | $160,815,645 |
| Gain On Sale Of Ppe | $26,771,075 | $15,997,478 | $9,459,744 | $-12,728,611 |
| Other Special Charges | $-14,715,157 | - | $-16,018,500 | - |
| Impairment Of Capital Assets | $36,987,598 | $17,794,829 | $31,532 | $7,347,068 |
| Gain On Sale Of Security | $43,556,865 | $51,250,790 | $36,020,602 | $32,594,073 |
| Research And Development | $252,869,464 | $287,786,430 | $240,414,135 | $203,710,328 |
| Selling General And Administration | $1,122,167,370 | $986,651,284 | $811,446,317 | $715,009,483 |
| Salaries And Wages | $629,693,105 | $586,504,119 | - | - |
| Write Off | - | - | $31,532 | $7,347,068 |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,723,470,765 | $2,362,571,027 | $2,515,724,279 | $2,059,039,379 |
| Total Assets | $6,089,405,289 | $5,181,721,845 | $4,073,134,464 | $3,382,951,552 |
| Total Non Current Assets | $2,915,398,457 | $2,552,838,008 | $1,465,934,461 | $1,236,083,707 |
| Other Non Current Assets | $3,384,486 | $2,333,403 | $9,302,081 | $1,387,429 |
| Non Current Prepaid Assets | $9,501,787 | $7,883,120 | $7,851,587 | $7,021,232 |
| Non Current Deferred Assets | $235,820,903 | $194,534,377 | $113,243,645 | $75,635,907 |
| Non Current Deferred Taxes Assets | $235,820,903 | $194,534,377 | $113,243,645 | $75,635,907 |
| Non Current Accounts Receivable | $36,356,949 | $19,140,215 | $39,079,253 | $28,242,591 |
| Investmentin Financial Assets | $112,413,289 | $109,217,998 | $11,130,965 | $6,937,145 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $28,768,132 | $14,095,018 | $8,513,769 | $3,973,092 |
| Goodwill And Other Intangible Assets | $1,239,773,007 | $1,141,612,399 | $433,088,095 | $368,866,945 |
| Other Intangible Assets | $1,104,256,921 | $1,017,479,538 | $388,385,550 | $324,248,487 |
| Current Assets | $3,174,006,832 | $2,628,883,838 | $2,607,200,002 | $2,146,867,845 |
| Other Current Assets | $63,306,708 | $29,072,946 | $29,125,500 | $54,393,527 |
| Hedging Assets Current | $1,629,178 | $5,854,530 | $1,776,330 | $12,949,338 |
| Prepaid Assets | $87,029,643 | $84,128,655 | $49,915,915 | $43,893,211 |
| Inventory | $804,404,063 | $747,162,102 | $667,984,046 | $511,561,926 |
| Receivables | $1,294,639,522 | $1,154,004,663 | $1,002,081,177 | $874,532,297 |
| Other Receivables | $230,744,174 | $203,615,731 | $158,082,831 | $112,655,038 |
| Accounts Receivable | $1,063,895,348 | $950,388,932 | $843,998,346 | $761,877,259 |
| Allowance For Doubtful Accounts Receivable | $-19,413,497 | $-15,535,002 | $-15,251,209 | $-13,222,620 |
| Gross Accounts Receivable | $1,083,308,844 | $965,923,934 | $859,249,556 | $775,099,879 |
| Cash Cash Equivalents And Short Term Investments | $922,997,718 | $608,660,941 | $856,317,035 | $649,537,545 |
| Cash And Cash Equivalents | $161,530,382 | $154,025,652 | $74,700,444 | $60,742,066 |
| Cash Equivalents | $11,751,104 | $26,392,685 | $27,170,487 | $28,831,197 |
| Cash Financial | $149,779,278 | $127,632,966 | $47,529,957 | $31,910,869 |
| Taxes Receivable | - | - | - | $28,242,591 |
| Assets Held For Sale Current | - | - | - | - |
| Debt | ||||
| Net Debt | $499,957,973 | $285,799,883 | $98,969,942 | $56,874,082 |
| Total Debt | $812,917,832 | $491,549,312 | $210,426,747 | $141,601,855 |
| Long Term Debt And Capital Lease Obligation | $128,263,616 | $82,657,140 | $62,959,851 | $13,432,836 |
| Long Term Debt | $128,263,616 | $39,941,141 | $39,941,141 | - |
| Current Debt And Capital Lease Obligation | $684,654,217 | $408,892,173 | $147,466,896 | $128,169,018 |
| Current Debt | $661,488,355 | $399,884,394 | $133,729,246 | $117,616,149 |
| Other Current Borrowings | $39,930,630 | - | $107,452,179 | $39,941,141 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,090,487,772 | $1,637,828,518 | $1,124,322,089 | $955,045,228 |
| Total Non Current Liabilities Net Minority Interest | $329,230,618 | $267,300,829 | $114,872,823 | $52,743,327 |
| Other Non Current Liabilities | $10,584,402 | $22,503,680 | $29,178,054 | $13,590,499 |
| Non Current Deferred Liabilities | $189,236,920 | $160,500,321 | $22,093,757 | $25,099,854 |
| Non Current Deferred Taxes Liabilities | $163,632,547 | $148,286,740 | $9,554,341 | $8,755,518 |
| Current Liabilities | $1,761,257,153 | $1,370,527,689 | $1,009,449,266 | $902,301,901 |
| Other Current Liabilities | $169,613,207 | $77,307,129 | $63,422,327 | $39,299,980 |
| Current Deferred Liabilities | $16,617,617 | $20,842,969 | $15,083,036 | $20,821,947 |
| Payables And Accrued Expenses | $811,015,373 | $798,654,641 | $726,897,228 | $656,684,907 |
| Payables | $517,553,097 | $534,465,017 | $466,407,415 | $427,086,413 |
| Other Payable | $237,208,332 | $291,864,630 | $215,314,281 | $216,859,372 |
| Total Tax Payable | $45,301,662 | $31,826,783 | $24,616,356 | $22,535,212 |
| Accounts Payable | $235,043,102 | $210,773,604 | $226,476,779 | $187,691,829 |
| Equity | ||||
| Common Stock Equity | $3,963,243,773 | $3,504,183,425 | $2,948,812,375 | $2,427,906,324 |
| Total Equity Gross Minority Interest | $3,998,917,518 | $3,543,893,328 | $2,948,812,375 | $2,427,906,324 |
| Stockholders Equity | $3,963,243,773 | $3,504,183,425 | $2,948,812,375 | $2,427,906,324 |
| Other Equity Interest | $110,815,644 | $39,310,491 | $40,561,279 | $49,474,460 |
| Gains Losses Not Affecting Retained Earnings | $41,822,579 | $41,822,579 | $6,863,570 | $9,312,592 |
| Other Equity Adjustments | $41,822,579 | $41,822,579 | $6,863,570 | $9,312,592 |
| Retained Earnings | $3,699,642,755 | $3,319,245,433 | $2,788,070,305 | $2,266,060,618 |
| Long Term Equity Investment | $59,627,919 | $50,567,586 | $44,103,428 | $49,421,906 |
| Other | ||||
| Treasury Shares Number | $23,184 | $25,775 | $15,230 | $19,505 |
| Ordinary Shares Number | $8,749,751 | $8,745,040 | $8,751,760 | $8,732,223 |
| Share Issued | $8,772,935 | $8,770,816 | $8,766,989 | $8,751,728 |
| Tangible Book Value | $2,723,470,765 | $2,362,571,027 | $2,515,724,279 | $2,059,039,379 |
| Invested Capital | $4,624,732,128 | $3,944,008,960 | $3,122,482,761 | $2,545,522,473 |
| Working Capital | $1,412,749,679 | $1,258,356,149 | $1,597,750,736 | $1,244,565,944 |
| Capital Lease Obligations | $151,429,477 | $51,723,777 | $36,756,360 | $23,985,706 |
| Total Capitalization | $3,963,243,773 | $3,544,124,566 | $2,988,753,515 | $2,427,906,324 |
| Minority Interest | $35,673,745 | $39,709,903 | $0 | - |
| Treasury Stock | $19,077,150 | $23,796,511 | $10,416,229 | $13,338,239 |
| Additional Paid In Capital | $121,263,405 | $118,835,404 | $114,967,420 | $107,641,374 |
| Capital Stock | $8,776,540 | $8,766,029 | $8,766,029 | $8,755,518 |
| Common Stock | $8,776,540 | $8,766,029 | $8,766,029 | $8,755,518 |
| Non Current Deferred Revenue | $25,604,373 | $12,213,580 | $12,539,416 | $16,344,335 |
| Long Term Capital Lease Obligation | $128,263,616 | $42,715,999 | $23,018,710 | $13,432,836 |
| Long Term Provisions | $1,145,680 | $1,639,689 | $641,160 | $620,139 |
| Current Deferred Revenue | $16,617,617 | $20,842,969 | $15,083,036 | $20,821,947 |
| Current Capital Lease Obligation | $23,165,862 | $9,007,778 | $13,737,650 | $10,552,870 |
| Line Of Credit | $621,557,725 | $399,884,394 | $133,729,246 | $77,675,008 |
| Current Provisions | $79,356,740 | $64,830,778 | $56,579,779 | $57,326,048 |
| Current Accrued Expenses | $293,462,276 | $264,189,624 | $260,489,813 | $229,598,494 |
| Investments And Advances | $172,041,208 | $159,785,584 | $55,234,393 | $56,359,052 |
| Other Investments | $112,413,289 | - | - | - |
| Available For Sale Securities | $83,645,157 | $95,122,980 | $2,617,196 | $2,964,053 |
| Goodwill | $135,516,086 | $124,132,861 | $44,702,545 | $44,618,458 |
| Net PPE | $1,218,520,116 | $1,027,548,909 | $808,135,406 | $698,570,551 |
| Accumulated Depreciation | $-1,091,717,505 | $-973,502,240 | $-980,176,614 | $-901,902,489 |
| Gross PPE | $2,310,237,621 | $2,001,051,149 | $1,788,312,021 | $1,600,473,040 |
| Construction In Progress | $161,961,326 | $261,067,909 | $151,986,551 | $104,645,789 |
| Machinery Furniture Equipment | $1,631,280,273 | $1,331,154,133 | $1,243,830,186 | $1,137,986,164 |
| Buildings And Improvements | $471,305,460 | $364,231,671 | $347,193,621 | $312,423,807 |
| Land And Improvements | $45,680,052 | $44,597,437 | $45,291,151 | $45,385,749 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $347,908,357 | $298,454,918 | $265,387,858 | $220,422,543 |
| Work In Process | $168,740,809 | $173,691,408 | $149,484,974 | $122,955,648 |
| Raw Materials | $287,754,897 | $275,015,775 | $253,111,213 | $168,183,735 |
| Other Short Term Investments | $761,467,337 | $454,635,289 | $781,616,591 | $588,795,479 |
| Other Properties | - | - | $31,532 | $31,532 |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $192,663,450 | $126,445,243 | $189,173,855 | $420,527,657 |
| Operating Activities | ||||
| Operating Cash Flow | $596,541,958 | $487,996,653 | $477,538,380 | $618,824,910 |
| Cash Flow From Continuing Operating Activities | $596,541,958 | $487,996,653 | $477,538,380 | $618,824,910 |
| Operating Gains Losses | $-33,739,753 | $-16,060,543 | $-16,617,617 | $-11,572,420 |
| Investing Activities | ||||
| Capital Expenditure | $-403,878,508 | $-361,551,410 | $-288,364,525 | $-198,297,253 |
| Investing Cash Flow | $-688,595,776 | $-610,437,271 | $-423,407,624 | $-434,864,425 |
| Cash Flow From Continuing Investing Activities | $-688,595,776 | $-610,437,271 | $-423,407,624 | $-434,864,425 |
| Capital Expenditure Reported | - | - | - | $-198,297,253 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-14,599,538 | $0 | $0 |
| Issuance Of Capital Stock | $4,172,798 | $2,028,590 | $8,461,215 | $3,867,984 |
| Financing Cash Flow | $87,134,752 | $198,770,240 | $-39,552,240 | $-282,331,311 |
| Cash Flow From Continuing Financing Activities | $87,134,752 | $198,770,240 | $-39,552,240 | $-282,331,311 |
| Cash Dividends Paid | $-69,991,594 | $-70,023,126 | $-69,875,975 | $-52,333,405 |
| Net Common Stock Issuance | $4,172,798 | $-12,570,948 | $8,461,215 | $3,867,984 |
| Common Stock Issuance | $4,172,798 | $2,028,590 | $8,461,215 | $3,867,984 |
| Dividends Received Cfi | $0 | $0 | $4,677,318 | $0 |
| Net Other Financing Charges | - | $74,164,392 | - | - |
| Other | ||||
| Repayment Of Debt | $-13,285,685 | $-13,601,009 | $-51,997,059 | $-10,668,489 |
| Issuance Of Debt | $0 | $0 | $39,941,141 | $0 |
| End Cash Position | $161,530,382 | $153,384,491 | $74,700,444 | $60,742,066 |
| Beginning Cash Position | $153,384,491 | $74,700,444 | $60,742,066 | $156,106,795 |
| Effect Of Exchange Rate Changes | $13,064,957 | $2,354,425 | $-620,139 | $3,006,096 |
| Changes In Cash | $-4,919,067 | $76,329,622 | $14,578,516 | $-98,370,825 |
| Interest Paid Cff | $-46,678,580 | $-36,609,209 | $-23,817,533 | $-19,476,562 |
| Common Stock Payments | $0 | $-14,599,538 | $0 | $0 |
| Net Issuance Payments Of Debt | $199,632,128 | $243,809,131 | $45,680,052 | $-214,389,328 |
| Net Short Term Debt Issuance | $212,917,812 | $257,410,141 | $57,735,970 | $-203,720,839 |
| Short Term Debt Issuance | $212,917,812 | $257,410,141 | - | - |
| Net Long Term Debt Issuance | $-13,285,685 | $-13,601,009 | $-12,055,918 | $-10,668,489 |
| Long Term Debt Payments | $-13,285,685 | $-13,601,009 | $-51,997,059 | $-10,668,489 |
| Long Term Debt Issuance | $0 | $0 | $39,941,141 | $0 |
| Interest Received Cfi | $15,986,967 | $35,442,507 | $14,063,486 | $8,166,912 |
| Net Investment Purchase And Sale | $-285,011,571 | $264,010,940 | $-165,062,019 | $-245,595,972 |
| Sale Of Investment | $206,033,221 | $563,485,409 | $272,692,883 | $1,185,673,783 |
| Purchase Of Investment | $-491,044,792 | $-299,474,469 | $-437,754,902 | $-1,431,269,755 |
| Net Business Purchase And Sale | $-33,666,177 | $-561,414,776 | $-126,130 | $0 |
| Purchase Of Business | $-33,666,177 | $-561,414,776 | $-126,130 | $0 |
| Net Intangibles Purchase And Sale | $-143,977,301 | $-64,767,713 | $-115,734,711 | $-79,283,164 |
| Sale Of Intangibles | $14,725,668 | $7,693,925 | $220,727 | $0 |
| Purchase Of Intangibles | $-158,702,969 | $-72,461,638 | $-115,955,438 | $-79,283,164 |
| Net PPE Purchase And Sale | $-241,927,694 | $-283,708,229 | $-161,225,568 | $-118,152,201 |
| Sale Of PPE | $3,247,845 | $5,381,543 | $11,183,519 | $861,888 |
| Purchase Of PPE | $-245,175,539 | $-289,089,772 | $-172,409,087 | $-119,014,088 |
| Taxes Refund Paid | $-142,169,439 | $-210,142,954 | $-210,710,539 | $-112,612,995 |
| Change In Working Capital | $-122,303,977 | $-315,209,176 | $-212,129,500 | $-82,562,542 |
| Change In Other Working Capital | $9,428,211 | $-76,655,458 | $30,029,431 | $5,549,716 |
| Change In Payables And Accrued Expense | $29,325,206 | $3,573,681 | $36,367,460 | $241,749 |
| Change In Payable | $29,325,206 | $3,573,681 | $36,367,460 | $241,749 |
| Change In Account Payable | $29,325,206 | $3,573,681 | - | - |
| Change In Inventory | $-90,403,619 | $-134,044,570 | $-193,872,195 | $-27,895,734 |
| Change In Receivables | $-70,653,776 | $-108,082,829 | $-84,654,197 | $-60,458,274 |
| Changes In Account Receivables | $-70,653,776 | $-108,082,829 | - | - |
| Other Non Cash Items | $126,130 | $1,597,646 | $-5,959,639 | $2,606,685 |
| Stock Based Compensation | $3,426,529 | $4,456,590 | $4,277,906 | $4,172,798 |
| Unrealized Gain Loss On Investment Securities | $-24,795,040 | $-37,355,477 | $-33,098,593 | $-9,207,484 |
| Provisionand Write Offof Assets | $7,252,470 | $1,692,243 | $2,890,477 | $2,154,719 |
| Asset Impairment Charge | $115,997,481 | $72,661,344 | $37,481,607 | $58,524,282 |
| Deferred Tax | $129,819,218 | $205,371,039 | $170,128,238 | $160,815,645 |
| Deferred Income Tax | $129,819,218 | $205,371,039 | $170,128,238 | $160,815,645 |
| Depreciation Amortization Depletion | $216,575,580 | $179,293,678 | $155,991,176 | $132,814,804 |
| Depreciation And Amortization | $216,575,580 | $179,293,678 | $155,991,176 | $132,814,804 |
| Amortization Cash Flow | $83,928,950 | $68,877,446 | $55,339,502 | - |
| Amortization Of Intangibles | $83,928,950 | $68,877,446 | $55,339,502 | - |
| Depreciation | $132,646,630 | $110,416,232 | $100,651,675 | - |
| Earnings Losses From Equity Investments | $-1,408,451 | $-2,280,849 | $-1,545,091 | $-3,889,006 |
| Net Foreign Currency Exchange Gain Loss | $-5,560,227 | $2,217,784 | $-5,612,781 | $-9,869,666 |
| Net Income From Continuing Operations | $446,352,758 | $601,692,263 | $585,284,863 | $473,691,418 |
| Short Term Debt Payments | - | - | - | $-203,720,839 |
Fetched: 2026-06-12